Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Research and Development Expenses : Rose to $53.0 million in Q4 and $189.1 million for the full year 2023. General and Administrative Expenses : Grew to $14.2 million in Q4 and $55.0 million for the full year 2023. Net Loss : Decreased to $14.4 million in Q4 and $147.0 million for the full year 2023. Cash Position : Strong with $745 million as of January 9, 2024, and runway into the first half of 2027. Warning! GuruFocus has detected 5 Warning Sign with KYMR. On February 22, 2024, Kymera Therapeutics Inc ( NASDAQ:KYMR ) released its 8-K filing , detailing the financial results for the fourth quarter and full year ended December 31, 2023. The biotechnology company, known for its pioneering work in targeted protein degradation, reported significant advancements in its clinical programs and a robust financial position. Company Overview Kymera Therapeutics Inc is at the forefront of developing innovative small molecule medicines through targeted protein degradation (TPD). T
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2GlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $53.00 price target on the stock.MarketBeat
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingGlobeNewswire
KYMR
Earnings
- 5/2/24 - Beat
KYMR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/24/24 - Form ARS
- KYMR's page on the SEC website